Abstract The role of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in normal brain function is not well understood. Studies looking at cognition in humans with GH deficiency have produced controversial results. Experiments in which GH is administered to rodents have shown an apparent improvement in learning and memory. However, studies in which GH deficient or resistant mice were tested in learning and memory tasks reveal that these animals have normal cognitive performance and that their neural function does not deteriorate with age at the same rate as their normal siblings. Further research into this phenomenon revealed that these animals have elevated GH and IGF-1 expression in the hippocampus compared to normal animals. Additional studies with GH deficient and resistant mice suggested that these mutants experience a delay in age-related decline in locomotor activity and exploratory behavior. Data indicate that GH/IGF-1 deficiency and resistance do not impair neural function and instead may offer some degree of protection that results in delayed cognitive and motor aging.
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Key words aging . cognition . delayed aging . dwarfism . growth hormone . learning and memory Abbreviations GH growth hormone IGF-1 insulin-like growth factor-1 GHRKO GH receptor knockout PRL prolactin TSH thyroid stimulating hormone Growth hormone (GH) levels vary with age from high prepubertal expression to a gradual decline from adulthood to death. This age-related reduction in GH is believed to result in a loss of muscle mass, bone density and energy levels, and an increase in adiposity (Rudman 1985; Meites 1988) . Indeed, several reports indicate that GH replacement can reverse many of these conditions as well as improve an individual's Bquality of life ( Rudman et al. 1990; Degerblad et al. 1990; Jorgensen et al. 1991; Almkvist et al. 1986; McGauley et al. 1990; Binnerts et al. 1992) . While these initial reports suggested that recombinant GH could be a new anti-aging drug, there are now concerns about whether GH treatment is actually harmful due to potential side effects (Laron 2005) . The adverse reactions reported are consistent with those present in humans and animals with high levels of GH, such as hyperinsulinemia and glucose intolerance, arthritis, hypertension, edema, congestive heart failure and possibly increased tumorogenesis (Vance 1990; Marcus et al. 1990; Moon et al. 1950; Cullen et al. 1990 ). Animal studies looking at GH treatment during aging found improvements in microvascular blood supply and partial reversal of age-related bone marrow loss and thymic regeneration French et al. 2002) . Further, it was reported that injections of GH prolonged life in mice but not in rats (Kalu et al. 1998; Khansari and Gustad 1991) . Although GH is used in middle-aged and elderly patients to improve physical and mental well-being, the harmful side effects make its use and value controversial.
While it is documented that GH expression decreases with age, the relationship between GH and longevity remains controversial. The pulsatile secretion of GH and the sensitivity to growth hormone releasing hormone (GHRH) stimulation decrease with age in both animals and humans (Muller et al. 1993) . However, studies attempting to determine how GH directly affects longevity have been troubled by the interference of other physiological alterations. For example, mice with elevated GH have a shortened lifespan (Steger et al. 1993a ). These animals overexpress insulin-like growth factor-1 (IGF-1) as expected, but they are also hyperinsulinemic, have elevated corticosterone levels and decreased cellular replication (Balbis et al. 1992; Cecim et al. 1996; Pendergast et al. 1993 ). In addition, hormone levels for several reproductive and neuroendocrine hormones are altered (Steger et al. 1993b; Bartke et al. 1994) . As a result, it is very difficult to isolate the effects of GH overexpression on longevity, but it appears as though GH excess is associated with reduced lifespan.
Likewise, animals that are GH deficient also have alterations in several systems such as metabolic, reproductive and stress response systems, but these animals also have increased lifespan. Several different mouse models of GH deficiency or resistance live longer than their normal siblings (Brown-Borg et al. 1996; Coschigano et al. 2000; Flurkey et al. 2001) . Taken together, it appears as though the absence of GH delays physical aging while increasing longevity.
While the specific mechanism for increased longevity in GH-IGF-1 deficient Ames dwarf mice and GH resistant GH receptor knockout (GHRKO) animals is unclear, the findings that longevity is capable of increasing in a given species are interesting. However, the quality of life for these long-lived animals remains in question. One aspect of importance is cognitive function. Studies assessing psychological profiles of GH-IGF-1 deficient/resistant humans and rodents have reported levels of intellectual capability varying from mental retardation to exceptional performance (Laron 1999; Meyer-Bahlburg et al. 1978; Sartorio et al. 1986; Frankel and Laron 1968; Galatzer et al. 1993; Kinney et al. 2001a,b; Kinney-Forshee et al. 2004) . Drotar et al. (1980) reported that GH deficient children were ineffective at problem-solving, while other studies have reported deficits in spatial orientation and visual motor integration Stahnke 1976, 1977; Steinhausen and Wefers 1976; Abbot et al. 1982) . Interestingly, many studies have reported normal intelligence and normal-to-good scholastic achievement for GH deficient/resistant children (Frisch et al. 1990; Holmes et al. 1984; Dean et al. 1985; Sartorio et al. 1986; Ranke 1987; Galatzer et al. 1987; Kranzler et al. 1998 ). In addition, Rosenbloom et al. (1996) reported exceptional school performance for GH receptor deficient children. Few studies have reported decreased intelligence quotient (IQ) in children with GH deficiency/resistance, but several studies have reported lower than normal academic achievement and more frequent grade retention in GH deficient/resistant children, indicating a disparity between IQ and academic achievement (Stabler 1991; Steinhausen and Stahnke 1976; Holmes et al. 1984; Money et al. 1967; Stabler 1991; Takano et al. 1994; Vicens-Calvert et al. 1993 ). These results suggest that the poor academic achievement frequently reported for these children could be the result of social factors instead of reduced intellectual capacity.
Studies assessing cognitive ability in adults with GH deficiency/resistance have produced more controversy regarding the effects of GH and IGF-1 on brain function. Kranzler et al. (1998) reported that in a population of Equadorian GH resistant (Laron) patients, intelligence was similar to normal relatives. Moreover, the GH resistant females in this population were characterized as Bexceptional school performers( Guevara-Aquirre and Rosenbloom 1993). Several studies have also reported that cognition is impaired in patients with either childhood-or adult-onset GH deficiency, and that their impairments were improved with GH treatment (Sartorio et al. 1996; Deijen et al. 1996; Burman et al. 1995; Deijen et al. 1998 ). Other studies report that GH treatment can improve feelings of vitality, mental alertness, and feelings of wellbeing in GH deficient adults (Degerblad et al. 1990; Jorgensen et al. 1991; Almkvist et al. 1986; McGauley et al. 1990 , Binnerts et al. 1992 . Sartorio et al. (1995) reported that improvements in feelings of well-being are reversed when GH treatment is discontinued after 6 months. However, Baum et al. (1998) failed to find changes in cognitive function or quality of life following 18 months of GH replacement in 40 men with adultonset GH deficiency. It is unclear whether replacing GH results in improvement in cognition and/or behavior in GH deficient patients. Moreover, the presence of cognitive and behavioral deficits in these patients has not yet been fully accepted and continues to be challenged.
Animal studies looking at the role of GH and/or IGF-1 in behavior, learning and memory have generally found GH to be beneficial to cognitive function in normal animals (Schneider-Rivas et al. 1995; Thornton et al. 2000) . The Schneider-Rivas study found that injections of either GH or GHRH facilitated learning and memory in an inhibitory avoidance task. However, enhanced performance was found in only the young (3-month-old) rats, while old (24-month-old) rats showed no improvement following injection. Thornton et al. (2000) administered GHRH to rats for 21 months followed by testing in the Morris water maze, a test of spatial learning and memory. When results from these animals were compared with 6-month-old age-matched control rats, those rats that had received GHRH injections were found to perform better than age-matched controls. The authors concluded that the administration of GHRH attenuated the typical age-dependent decrease in learning and memory capability, although it is difficult to isolate the specific cause of these improvements without further studies.
The various dwarf mice, including the growth hormone receptor knockout (GHRKO) and Ames dwarfs, provide a valuable resource for studying the effects of GH and IGF-1 on brain function. The Ames dwarf mice have a primary pituitary deficiency resulting in the failure of adenohypophyseal somatotroph, lactotroph and thyrotroph development (Bartke 1964) . These mice have a homozygous mutation in the Prop-1 locus on chromosome 11, resulting in deficiencies in GH, prolactin (PRL), and thyroid stimulating hormone (TSH) (Sornson et al. 1996; Bartke et al. 2001) . The GHRKO mice have a mutation in the GH receptor, making them GH resistant (Zhou et al. 1997 ). Both models of GH deficiency have a dwarf phenotype and increased longevity. The increased longevity makes these mice valuable models in which to study the aging brain.
Tests of locomotor activity in the GH-R-KO mice failed to find an age-related reduction in activity levels compared to their younger counterparts, whereas old normal animals showed a reduction in activity compared to their younger counterparts (B.A. Kinney-Forshee, unpublished data) . Results for the open field test revealed a similar preservation of locomotor activity in GHRKO mice when compared to normal siblings (Kinney-Forshee et al. 2004 ). These findings are in contrast to the gradual decline in locomotor activity previously reported in rhesus monkeys and in several strains of rodents (Moscrip et al. 2000; Weinert and Waterhouse 1999) .
Results for locomotor activity testing in the stocks segregating for Ames dwarfism indicate that neither normal nor dwarf mice experience an age-related reduction in locomotor activity. While the old normal animals were more active than the old dwarf animals, the old dwarf animals were more active than the young dwarfs (Kinney et al. 2001b) .
While more locomotor tests must be completed in these animals to determine whether GH deficiency/resistance alters age-related changes in locomotor activity, there is a trend suggesting that the GH resistant animals do not experience the same age-related decline in locomotor activity as normal animals of this strain. Also, the tests of the Ames dwarf mice and the GH-R-KO mice were completed at different chronological ages, which may suggest that the delay in age-related changes is apparent at middle age and becomes minimal as the animals reach elderly status.
Study of elevated plus maze activity in Ames dwarf mice and their normal siblings support results obtained in previous studies with the Senescence-Accelerated mouse (SAM) performed by Miyamoto et al. (1992) , in that the old groups appeared to experience a decline in anxious behavior compared to the young groups (Kinney et al. 2001b ). Both young normal and young Ames dwarf mice exhibited much more anxious behavior compared to the old groups, whereas the old normal and Ames dwarf mice did not differ from each other. Taken together, it appears that both the old normal and dwarf animals were less anxious than their younger counterparts, and that the dwarf animals showed no clear delay in age-related reduction in anxious-like behavior. Perhaps this finding suggests that GH/IGF-1 deficiency does not positively influence the primary areas of the brain responsible for emotionality.
An open-field test for the Ames dwarf strain contradicted the elevated plus maze results (Kinney-Forshee et al. 2004) . In this test there were clear differences in exploratory behavior between young and old normal animals but no differences between young and old Ames dwarf mice. Further, young normal animals spent less time exploring open areas when compared to their older counterparts, implying anxious behavior. Such differences in emotionality were not found in the young and old Ames dwarf mice. In fact, the young and old Ames dwarf mice did not differ on any measure of this test, implying that the old Ames dwarf mice may not experience a reduction in anxious-like behavior at the same rate as their normal siblings.
The apparent differences in findings between the elevated plus maze and the open field test could be due to differences in the ages of animals used in each test. The animals used in the open field test were younger than those used in the elevated plus maze. In fact, those used in the elevated plus maze were near the end of their lifespan. Perhaps these results indicate that the Ames dwarf mice do experience an increase in anxiety-like behavior with age, but they do not experience this increase at the same rate as their normal siblings. Very different results were obtained when the GHRKO mice were tested in the elevated plus maze. Results for these tests failed to find genotype-related differences in emotionality between old normal and old GHRKO mice in this strain (Kinney et al. 2001a) .
Cognitive testing revealed the most striking differences between old mutants and their normal siblings. In inhibitory avoidance studies, both the Ames dwarf and the GHRKO mice did not show cognitive decline at the rate of their normal siblings. While the old normal animals in the Ames dwarf strain performed poorly on the 15-day retention test, the old Ames dwarf animals had a much smaller decline in retention. Although the old dwarf animals did not differ from the old normals in retention performance, they also did not differ from the young groups (Kinney et al. 2001b) . Further, the age of the old dwarf group was 22-29 months, whereas the old normal group was 20-23 months. At these ages, both of these groups were equivalent to about late middle-age and nearly the same biological age. While further studies need to be done with older dwarf animals, the findings presented here suggest that dwarfs may not experience the expected cognitive decline as quickly as normal animals.
Similar findings were obtained in two separate avoidance learning tests with GHRKO mice (Kinney et al. 2001a) . The inhibitory avoidance studies using GHRKO looked at learning and memory in two separate paradigms. The first utilized a repeated-measures design, in which the same animals were tested in three separate retention tests. Results from this study showed that over time, memory in old normal animals declined whereas old GHRKO mice showed no significant decline. The second study subjected the animals to independent retention tests. There were no differences between GHRKO and normal mice in the 24 h retention test, but by the 7-day retention test, the old normal animals had poorer retention than their young counterparts. The 28-day test also revealed a greater decline in long-term memory for the normal animals compared to their younger counterparts, whereas the memory of GHRKO mice did not change significantly or differ from their younger counterparts.
Taken together, these results suggest that GH deficient/resistant animals are not learning impaired and that the delay in physiological aging seen in these mice is paralleled by a delay in cognitive aging.
Water maze learning tests revealed findings similar to the inhibitory avoidance test for the GHRKO strain but very different results for the young and old Ames dwarf mice. Like the inhibitory avoidance test, the old normal animals of the GHRKO strain performed poorly compared to the old GHRKO and the young normal and GHRKO mice, while the latter three groups did not differ from each other (Kinney-Forshee et al. 2004 ). In the Ames dwarf strain, old normal animals also did not perform as well as their younger counterparts but fared better than the old dwarf animals. Additionally, old dwarf animals performed more poorly than their younger counterparts (B. A. Kinney, unpublished data). These findings are in contrast to those for the inhibitory avoidance task, in which old normal animals showed deficits in retention but old Ames dwarf animals performed no different than young normal and Ames dwarf groups. Perhaps the discrepancies in test results were due to the decline in locomotor activity seen in young and old dwarf animals.
There are several possible physiological factors that may contribute to the apparent delay in cognitive aging seen in GHRKO mice. Perhaps GH deficiency/resistance indirectly delays brain aging by altering the activity of other hormones and/or neurotransmitters. In addition, GH deficiency/ resistance induces a reduction in basal glucose levels and enhancement of insulin sensitivity (Borg et al. 1995) . Also, the Ames dwarf mice exhibit elevated catalase activity in liver and kidney, elevated catalase and superoxide dismutase activity in the hypothalamus and some indications of reduced oxidative damage compared to controls (Brown-Borg et al. 1999; Brown-Borg and Rakoczy 2000; Hauck and Bartke 2000; Sanz et al. 2002) . Previous studies have suggested that the age-induced increase in oxidative damage may be an important factor in cognitive deficits seen during aging (Forster et al. 1996) .
Recently, it was suggested that IGFs, brainderived neurotrophic factor (BDNF) and serotonin may stimulate proteins involved in learning and memory, cellular stress adaptation, growth and repair, cell survival and neurogenesis (Mattson et al. 2004) . Several studies have revealed the importance of GH/IGF-1 for cognitive function. Shi et al. (2005) found that 28-day IGF-1 treatments appeared to enhance synaptic efficacy. Although the Ames dwarf mice are GH and IGF-1 deficient, hippocampal GH and IGF-1 and neurogenesis in the dentate gyrus are increased in adult Ames dwarf mice compared to normal siblings (Sun et al. 2005a,b) . These results may explain the delayed cognitive aging seen in these mice as well as in the GHRKO mice.
Much work is still needed to determine the role of GH/IGF-1 on learning and memory and whether the key to delayed cognitive aging is maintenance of hippocampal IGF-1 levels. To date it is undetermined whether GH deficiency leads to mental impairment and whether treatments in GH deficient patients improve brain function. Animal studies have revealed that GH/IGF-1 treatments appear to be beneficial to cognitive function and may reduce age-related cognitive decline. Work with mutant GH deficient/resistant animals shows that, in addition to delayed physical aging and longer lifespans, the Ames dwarf and GHRKO mice maintain their cognitive abilities longer than their normal siblings. Further studies looking at hippocampal gene expression revealed that GH and IGF-1 were expressed at higher levels in the hippocampus of Ames dwarf mice compared to their normal siblings. Taken together, these studies suggest that GH/IGF-1 deficiency/resistance does not result in impaired brain function and that these conditions may provide neural protection that delays the normal age-related decline in cognitive function. Van De Kar L et al (1996) Increased plasma corticosterone levels in bovine growth hormone (bGH) transgenic mice: effect of ACTH, GH and IGF-1 on in vitro adrenal corticosterone production. 
